In fairness, the quarterly did mention DEP Gemcitabine as (still) at the pre-clinical stage. I wonder if they are trying to find someone else to pay for the trial? Regardless of how long it takes.
Business development activities for DEP® cabazitaxel, DEP® irinotecan, and DEP® docetaxel are ongoing. Other internal preclinical DEP® programs including DEP® radiotheranostics, DEP® ADCs, and DEP® gemcitabine continue to progress, with ongoing commercial discussions in parallel.
SPL Price at posting:
50.0¢ Sentiment: Hold Disclosure: Held
